Iterative Therapeutics, Inc.
Records under this name other than patents Iterative Therapeutics, Inc. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned.
Showing 1 to 5 of 5 · Back to Iterative Therapeutics, Inc.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 7,511,121 | Polymeric immunoglobulin fusion proteins that target low-affinity Fcγreceptors Term ended Term ended Nov 29, 2022 · From the USPTO record | Term ended | Term ended Nov 29, 2022 | From the USPTO record |
| US 7,897,729 | Polymeric immunoglobulin fusion proteins that target low affinity FcγReceptors Term ended Ended no later than Mar 11, 2022 · From the USPTO record | Term ended | Ended no later than Mar 11, 2022 | From the USPTO record |
| US 8,163,289 | Methods and Compositions Involving Polymeric Immunoglobulin Fusion Proteins Term ended Term ended Mar 11, 2022 · Medium confidence | Term ended | Term ended Mar 11, 2022 | Medium confidence |
| US 8,986,698 | Method of using fusion proteins Term ended Term ended Mar 11, 2022 · From the USPTO record | Term ended | Term ended Mar 11, 2022 | From the USPTO record |
| US 9,127,063 | Nucleic acids related to fusion proteins Term ended Term ended Mar 11, 2022 · From the USPTO record | Term ended | Term ended Mar 11, 2022 | From the USPTO record |